Cumulative incidence of developing a subsequent solid neoplasm, by source, overall, and by HCT type. Cumulative incidence of developing a solid SN (excluding NMSC and other/unknown neoplasms) for all patients combined (A), following alloHCT (B), and following autoHCT (C). Includes SNs diagnosed after 1990, after first HCT and before the end of follow-up (defined as the earliest occurrence of a second HCT, death, last known alive status from either CCR or CIBMTR, or the study end date [31 December 2018]). Cumulative incidence at 10 years following HCT shown in text.